WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2014207601) HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS
Latest bibliographic data on file with the International Bureau   

Pub. No.: WO/2014/207601 International Application No.: PCT/IB2014/062217
Publication Date: 31.12.2014 International Filing Date: 13.06.2014
IPC:
C07D 401/14 (2006.01) ,C07D 405/14 (2006.01) ,C07D 401/12 (2006.01) ,A61K 31/513 (2006.01) ,A61K 31/501 (2006.01) ,A61K 31/497 (2006.01) ,A61P 25/00 (2006.01)
Applicants: PFIZER INC.[US/US]; 235 East 42nd Street New York, New York 10017, US
Inventors: BRODNEY, Michael Aaron; US
DAVOREN, Jennifer Elizabeth; US
DOUNAY, Amy Beth; US
EFREMOV, Ivan Viktorovich; US
GRAY, David Lawrence Firman; US
GREEN, Michael Eric; US
HENDERSON, Jaclyn Louise; US
LEE, Chewah; US
MENTE, Scot Richard; US
O'NEIL, Steven Victor; US
ROGERS, Bruce Nelsen; US
ZHANG, Lei; US
Agent: KLEIMAN, Gabriel L.; 235 East 42nd Street Mail Stop 235/9/64 New York, New York 10017, US
Priority Data:
61/840,14427.06.2013US
Title (EN) HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS
(FR) COMPOSÉS HÉTÉRO-AROMATIQUES ET LEUR UTILISATION EN TANT QUE LIGANDS D1 DE LA DOPAMINE
Abstract: front page image
(EN) The present invention provides, in part, compounds of Formula (I) and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D1 -mediated (or D1 -associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD, PD, or pharmacotherapy therapy), age-related cognitive decline, dementia, and Parkinson's disease.
(FR) La présente invention concerne, en partie, des composés représentés par la formule (I) : (I) et leurs sels pharmaceutiquement acceptables ; des procédés pour leur préparation ; des intermédiaires utilisés dans leur préparation ; et des compositions contenant de tels composés ou sels et leurs utilisations pour le traitement de pathologies médiées par le D1 (ou associées au D1), notamment la schizophrénie (par ex., ses symptômes cognitifs et négatifs), le déficit cognitif (par ex., le déficit cognitif associé à la schizophrénie, la MA, la MP ou une pharmacothérapie), le déclin des facultés mentales lié à l'âge, la démence et la maladie de Parkinson.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)